Alector, Inc. (ALEC)


5.73 +0.19 (3.43%)

At close: Jul 15, 2024, 4:00 PM

Company Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Key Executives

Dr. Marc Grasso M.D.Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Dr. Saraswati Kenkare-Mitra Ph.D.President and Head of Research & Development
Ms. Kristina Cutter M.P.H.Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer
Ms. Danielle Pasqualone J.D., Ph.D.General Counsel
Ms. Virginia DeJesus-Rueff M.B.A.Chief of Staff & Head of Strategy
Katie HoganSenior Director of Corporate Communication & Investor Relations
Dr. Arnon Rosenthal Ph.D.Co-Founder, Chief Executive Officer & Director
Dr. Gary Romano M.D., Ph.D.Chief Medical Officer
Mr. Peter Heutink Ph.D.Chief Scientific Officer
Ms. Clare Hunt M.B.A.Chief People Officer

Alector, Inc.

Alector, Inc. logo.
IPO DateFebruary 07, 2019
CEODr. Arnon Rosenthal Ph.D.

Contact Details

131 Oyster Point Boulevard
South San Francisco, CA
Phone:415 231 5660